-
Jul 24, 2024 | 
tandfonline.com | Justin Faden |Vanessa Martinez |Leslie Citrome |Camila Ramirez
ABSTRACTIntroduction Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development.
-
May 17, 2024 | 
gastroenterologyadvisor.com | Vanessa Martinez
In this physician profile, we spoke with Edwin Liu, MD, a pediatric gastroenterologist and director of the Colorado Center for Celiac Disease at Children’s Hospital Colorado. Dr Liu also serves as Taplin Endowed Chair for Celiac Disease and is a founding member of the Society for the Study of Celiac Disease and board member for the International Society for the Study of Celiac Disease.
-
Apr 26, 2024 | 
clinicaladvisor.com | Vanessa Martinez
Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Colorectal cancer (CRC), a collective term for colon and rectal cancers, is the third leading cause of cancer-related deaths among men and the fourth leading cause among women in the United States.1However, there are ways to reduce risk for CRC — and even stop it from spreading.
-
Apr 26, 2024 | 
clinicaladvisor.com | Vanessa Martinez
Beyond performing a differential diagnosis, how can clinicians manage gastroparesis that results from a GLP-1 receptor agonist like semaglutide?
-
Mar 20, 2024 | 
brnw.ch | Vanessa Martinez
Our easy-to-read fact sheets provide clinicians with reliable information to share with patients and their caregivers. Colorectal cancer (CRC), a collective term for colon and rectal cancers, is the third leading cause of cancer-related deaths among men and the fourth leading cause among women in the United States.1However, there are ways to reduce risk for CRC — and even stop it from spreading.
-
Nov 7, 2023 | 
pulmonologyadvisor.com | Vanessa Martinez
Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA).1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating.2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of gastroparesis.3 Recent reports have revealed that patients who receive semaglutide-containing medications, such...
-
Oct 10, 2023 | 
renalandurologynews.com | Vanessa Martinez
Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA).1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating.2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of gastroparesis.3 Recent reports have revealed that patients who receive semaglutide-containing medications, such...
-
Oct 10, 2023 | 
brnw.ch | Vanessa Martinez
Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA).1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating.2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of gastroparesis.3 Recent reports have revealed that patients who receive semaglutide-containing medications, such...
-
Sep 26, 2023 | 
medicalbag.com | Vanessa Martinez
Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA).1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating.2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of gastroparesis.3 Recent reports have revealed that patients who receive semaglutide-containing medications, such...
-
Sep 25, 2023 | 
brnw.ch | Vanessa Martinez
Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA).1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating.2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of gastroparesis.3 Recent reports have revealed that patients who receive semaglutide-containing medications, such...
